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Background: Intra-articular stem cell therapy may help alleviate lameness caused by
osteoarthritis in dogs. Umbilical cord-derived stem cell (UMSC) therapy has not yet
been investigated in a veterinary clinical study. We hypothesized that dogs treated with
intra-articular UMSC will have improved limb function and quality of life when compared
to dogs treated with a saline placebo injection.
Methods: This was a prospective, double-blinded, placebo-controlled clinical trial in
client-owned dogs with chronic elbow osteoarthritis with a follow-up time of 6 months.
Dogs were assigned to receive intra-articular UMSC (n = 38) or a saline placebo
intra-articular injection (n = 30). Outcome measures included the Canine Brief Pain
Inventory score (CBPI) and peak vertical force (PVF) from force-platform gait analysis.
Treatment was considered successful when there was a decrease in the Pain Severity
Score of at least one and a decrease in the Pain Interference Score of at least one from
baseline. Success rates and PVF were compared between groups.
Results: No adverse effects associated with UMSCwere noted. Of the dogs completing
the study, treatment success in the UMSC (n = 28) vs. placebo groups (n = 23) was
observed in 54 vs. 28% of dogs at 1 month, 50 vs. 27% at 3 months, and 46 vs. 14%
at 6 months, respectively. Success rate in the UMSC group was significantly higher than
the placebo group at 1 and 6 months after treatment. However, no differences in PVF of
the affected limb over time was observed in either group.
Conclusions: Intra-articular UMSC for osteoarthritis may improve clinical signs based
on owner observations.
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INTRODUCTION
Osteoarthritis (OA), or degenerative joint disease, is the
most common cause of chronic pain affecting dogs in
the United States (1). Adult articular cartilage has limited
regenerative capability, which makes OA a progressive disease
and challenging to treat. The goal of OA treatment is to reduce
pain and increase limb function while improving quality of life.
Common conventional non-surgical treatment options include
the administration of non-steroidal anti-inflammatory drugs
and poly-sulfated glycosaminoglycans, as well as nutritional
and behavior modifications. Many of these therapeutics are
thought to alleviate arthralgia by mitigating inflammation. These
conventional treatment modalities have limited efficacy and
duration of action, are not curative, and can be associated with
adverse effects (2).
Mesenchymal stem cells (MSC) have been investigated for the
treatment of OA in dogs (3–13). While the precise mechanism
of action is unknown, the therapeutic effect of MSC for
OA is predominately attributed to their anti-inflammatory
properties (14). Studies evaluating the efficacy of adipose derived
and bone marrow derived MSC delivered intra-articularly in
animal models of induced and spontaneous OA have shown
improvements through various outcome measures (6–11), with
encouraging results for the application of MSC for the treatment
of OA in a clinical setting (3–5, 7–10). Black et al. found
subjective improvements in lameness, pain, and range of motion
in dogs with elbow and hip OA treated with intra-articular
autologous stromal vascular fraction containing adipose derived
MSC (3, 4). More recently, Vilar et al. reported a significant
increase in peak vertical force (PVF) and vertical impulse
(VI) on force plate analysis in dogs with hip OA 6 months
following treatment with intra-articular autologous adipose-
derived MSC (9, 10). However, most of the studies investigating
MSC have several limitations including lack of randomization or
control group, small sample size and/or only subjective outcome
measures (3–5, 9, 10).
Most of the commercially available stem cell therapies in
dogs are autologous, and therefore require retrieval of tissue
or fluids from the subject undergoing treatment. This multi-
step process creates a time lag between the decision to treat
and delivery of stem cells. More importantly, harvest of stem
cells typically requires surgery and is therefore associated
with additional morbidity and cost. These limitations can be
overcome by using allogenic MSC, which could be considered
as being available “off-the-shelf.” In a recent study, intra-
articular administration of allogenic adipose derived MSC was
considered efficacious when compared to a saline placebo
in dogs with OA (7). An alternate source of MSC is the
umbilical cord. Umbilical cord derived MSC (UMSC) have
the advantage of utilizing “waste” tissues that are collected
during a cesarean section planned for reasons unrelated to
UMSC harvest (12, 15). Additional advantages of UMSC
over MSC sourced from other sites include acquisition of
younger cell types that have a higher capacity to proliferate
with wide differentiation potential (15). While UMSC have
several promising theoretical advantages, the risks and overall
therapeutic response when used for treating OA in dogs
are unknown.
The aims of this study were to evaluate the efficacy and
safety of intra-articular allogeneic UMSC for the treatment of
chronic elbow OA in dogs. We hypothesized that dogs treated
with intra-articular UMSC would have improved limb function
and quality of life when compared to dogs treated with a saline
placebo injection.
MATERIALS AND METHODS
This study was a prospective, double-blinded, placebo-controlled
clinical trial at the University of Florida Small Animal Hospital.
All procedures were approved by the University of Florida
Institutional Animal Care and Use Committee, as well as the
Veterinary Hospital Research Review Committee.
Selection Criteria
Client-owned dogs with clinical signs of elbow OA were
considered for enrollment. Owner consent was obtained prior
to screening; the consent form detailed the study protocol
including the screening procedures. To be eligible for inclusion,
dogs had to be >12 months and <11 years of age, weigh
between 13 and 60 kg, have a visibly apparent unilateral forelimb
lameness upon examination by a board-certified veterinary
surgeon, and have a chronic (≥6 months) history of forelimb
lameness. Lameness must have been attributable to elbow
OA based on orthopedic examination by a board-certified
veterinary surgeon, including pain or resistance on elbow
manipulation, as well as evidence of OA on diagnostic imaging.
Owners completed the Canine Brief Pain Inventory (CBPI)
survey [(15), https://www.vet.upenn.edu/research/clinical-trials-
vcic/our-services/pennchart/cbpi-tool/cbpi-tool-form] and they
must have reported both the baseline pain severity (PSS) and pain
interference (PIS) scores of ≥2 for their dog.
The presence of osteoarthritic changes in the elbow(s) was
confirmed by CT imaging of the forelimbs from mid-humerus
to mid-radius and ulna. For CT imaging, dogs were sedated
with dexmedetomidine at 10–15 µg/kg intravenously; during
image acquisition, dogs were positioned in dorsal recumbency
with the forelimbs extended cranially, and both elbows were
scanned at the same time. Each case was assessed for the presence
of unilateral or bilateral elbow OA on CT images; the degree
of OA was not graded, but only assessed as being present or
absent. Underlying pathology such as medial coronoid disease,
radio-ulnar incongruency, osteochondritis was identified and
recorded. Confirmation of general good health was achieved with
a complete physical examination by a veterinarian, review of
medical history, and clinical pathology evaluations (CBC, serum
biochemistry profile, and urinalysis). Dogs on neutraceuticals
and/or medications such as non-steroidal analgesic drugs
(NSAID) must have been on a stable dose for at least 4 weeks
prior to the start of the study, and throughout the study duration.
Dogs were excluded if they had forelimb lameness attributable
to disease(s) other than elbow OA, hindlimb lameness of
any cause, cranial cruciate ligament insufficiency, neurologic
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disease, malignancy, septic arthritis, current administration of
tetracycline antibiotics (due to possible immunomodulatory
effects), any febrile disease, immune mediated disease, or other
concurrent systemic disease that might limit the dog’s lifespan.
Dogs with bilateral elbow OA were considered candidates for the
study if lameness was unilateral or if there was an asymmetric
bilateral forelimb lameness.
At the initial evaluation and all rechecks, force plate evaluation
was performed at a trot (16). Gait analysis was performed at trot
because lameness may be more apparent at the trot rather than
walking. Approximately 15–20 passes of combined left and right
forelimbs were collected, and the most representative 5 passes
per limb were analyzed. Asymmetry in PVF of ≥4 N/kg between
forelimbs on force-plate analysis must have been evident the time
of screening for inclusion into the study; the side of lameness on
force plate analysis must also have corresponded to the owner’s
observation of the most affected side.
Treatment Allocation
Dogs were allocated into either UMSC or placebo groups
according to the method of minimization. Because true
randomization requires very large numbers, the method of
minimization is often used to stratify groups in clinical trials
(17). The method of minimization requires identifying several
factors that are most likely to affect the outcomes of the study
and attempts to balance these factors equally across the two
groups. In this trial, the factors considered were the degree of
lameness based on force-plate evaluation, the use of non-steroidal
anti inflammatories, body condition score, and age. The study
coordinator, who was a veterinarian, determined the allocation
of dogs based on these factors in the order listed above. In
dogs with bilateral lameness, only the clinically worse elbow
was injected.
Blinding
The treatment allocation was known only to the study
coordinator. The intra-articular treatment was performed by the
study coordinator in the absence of any individual that was
involved in case evaluations. The owners, all other veterinarians,
and all clinic personnel who were involved in the study were
blinded to treatment group.
Stem Cell Collection and Preparation
Canine umbilical cords were collected at veterinary hospitals
from healthy donor puppies who met Animal Cell Therapies’
donor eligibility criteria at the time of cesarean section in an
aseptic manner. Dams must have been considered systemically
healthy upon physical examination, current on vaccinations
(Rabies and Distemper), negative and on preventative for
heartworm disease, negative for occult infectious diseases
including Anaplasma spp., Babesia spp., Bartonella spp., Brucella
canis, Canine Hemotropic Mycoplasma, Ehrlichia spp., and
Leishmania spp. based on PCR on serum. The placenta and
umbilical cords were placed in cold sterile transport medium
and sent to the processing facility. Umbilical cords were
processed according to the U.S. Food and Drug Administration
(FDA) Good Tissue Practices, under sterile conditions. The
cells were mainly derived from Warton’s jelly. Briefly, using
sterile instruments and technique, the cord tissues were
washed until mostly blood-free. After removing the remaining
placentas and major blood vessels, the cord tissues were
digested with an enzyme solution. After enzymatic digestion, the
cells released from the tissues were pelleted by centrifugation
and seeded on cell culture vessels. Cells were cultured with
proprietary culture medium and maintained using standard cell
culture techniques. Each 0.5ml dose contained approximately 7
million cells.
Master and working cell banks were generated according
to Animal Cell Therapies SOPs under the FDA Current
Good Manufacturing Practices. The UMSC were tested for
mycoplasma, endotoxin, fungal, aerobic and anaerobic bacteria,
and cell viability was quantified prior to lot release. Additionally,
after processing, the passage one cells were further tested
for canine blood donor pathogens using PCR. The cells
were characterized to conform to Animal Cell Therapies’
standard growth curves, tri-lineage (adipocyte, osteocyte, and
chondrocyte differentiation) potency assays and cell surface
marker expression. Positive markers for canine umbilical cord
tissue derived MSC analyzed by flow cytometry included
CD44, CD90, CD105, and negative markers included CD45,
CD34, CD14, CD19, and MHC-II. Prior pilot investigations
(unpublished data) found cell viability before shipping of 98%,
and average cell viability of 92% (ranged from 88 to 95%)
at the destination (cell viability was determined roughly 24 h
after packing).
Treatment
Dogs underwent treatment with either intra-articular UMSC
therapy (UMSC group) or placebo injection using 0.9% NaCl
(placebo group) within 2 weeks of screening and recruitment.
For all dogs, sedation with dexmedetomidine at 10–15 µg/kg
intravenously was performed for the purposes of arthrocentesis
and joint injection. After aseptic preparation, arthrocentesis
was performed in a sterile manner at the mid-medial aspect
of the elbow joint; <0.5ml of the joint fluid was removed
and then evaluated cytologically to ensure it was consistent
with OA.
All treatments (placebo and UMSC) were kept on ice until
5min prior to injection, then thawed at room temperature.
The UMSC suspension was gently agitated before being drawn
into a sterile syringe. The preplaced 22 g hypodermic needle
used for arthrocentesis was used to administer 0.5ml of UMSC
suspension or 0.5ml of sterile saline. Sedation was reversed with
atipamezole at 100–150 µg/kg administered intramuscularly.
Owners were advised to monitor the treated joint for signs of
infection or inflammation (redness, swelling, discharge, acutely
worsening lameness, lethargy). Owners were also advised to
restrict their dog’s activity for 2–3 days following joint injection.
If no signs of discomfort were noted, dogs were permitted normal
activity. Dogs were withdrawn from the study at any time due to
unacceptable outcomes such as deterioration of limb use and/or
the development of a serious adverse event. Dogs in the placebo
group were eligible for an intra-articular dose of UMSC at their 6
months evaluation or at the time of withdrawal.
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Outcome Measures
Data was scheduled for collection immediately prior to treatment
(day 0), then at day 30, 90, and 180 following treatment. At each
time point, owners scored the level of pain with the CBPI (18),
and degree of lameness with the Hudson Visual Analog Scale
(HVAS) (19). Owners and evaluators did not see their prior scores
when completing the new scoring forms. Dogs also underwent
force-platform gait analysis as described above, and veterinary
orthopedic examination. For force-platform gait analysis, the
symmetry index was calculated according to the formula (20):
Symmetry Index = (0.5×[PVFa − PVFc])/(PVFa − PVFc)×100%,
where PVFa =mean peak vertical force of the affected fore limb,
and PVFc = mean peak vertical force of the contralateral fore
limb. The CBPI questionnaire is a validated two-part instrument:
the PSS is the mean of four items scored on an 11-point
(0–10) numerical scale, and the PIS is the mean of 6 items
scored similarly (18). In addition, the CBPI includes a single
question for the owner to rate his or her overall impression
of the dog’s quality of life over the last 7 days using the
following terms (owner chose one): poor, fair, good, very good,
or excellent. The HVAS questionnaire, another validated clinical
outcomes tool, required owners to mark the degree of pain and
lameness on a 10 cm horizontal line with positive and negative
descriptors of lameness provided at opposing ends of the scale
(19). Orthopedic assessment was performed by a board certified
veterinary surgeon. Lameness was evaluated at a walk, trot, and
standing. The surgeon evaluated joint effusion, muscle mass,
range of motion, crepitus, and remodeling (joint thickening) by
direct visualization and palpation on a scale of 0–5 (0 = normal,
1 =mild, 2 =mild to moderate, 3 =moderate, 4 =moderate to
severe, and 5= severe).
Adverse Events
Safety was monitored through the development of adverse
events throughout the study period. Any adverse event following
treatment was recorded, regardless of its suspected relationship
to the treatment. Serious and non-serious adverse events, defined
according to FDA guidelines, were included (21). Non-serious
events were further qualified as mild (not interfering with the
dog’s usual function), moderate (interfering somewhat with
the dog’s usual function), and severe (interfering significantly
with the dog’s usual function). Adverse events were assessed in
regards to their suspected relationship to the treatment, and
were classified as definite (distinct temporal relationship between
the treatment and the known reaction), probable (reasonable
temporal relationship between the treatment and the reaction),
possible (reasonable temporal relationship between the treatment
and the reaction, but the reaction could also be explained by the
patient’s clinical state or other factors), unlikely (poor temporal
relationship between the treatment and the reaction, and the
reaction is easily explained by other factors), or unrelated (the
event occurred prior to the treatment, or the reaction can be
completely explained by other factors).
Statistical Analysis
Based on a pre-study power analysis using results from a pilot
field study at our institution, 25 dogs per treatment group was
found to provide >90% power with α = 0.05 in detecting a
difference in treatment success rate of 20% based on CBPI (as
defined below). In order to account for attrition during the study,
we aimed to recruit 30 dogs per group.
Safety was assessed in the intent-to-treat (ITT) population,
which included all dogs that received treatment (UMSC and
placebo). The rate and type of adverse events were noted and
descriptively compared for each treatment group.
The UMSC and placebo group populations were assessed for
differences in pre-treatment variables with an unpaired t-test for
age, orthopedic score, CBPI, and HVAS (all normally distributed
according to Shapiro-Wilks test), and with a Chi-Squared test for
NSAID use.
Efficacy was determined from the Per Protocol Population
(PPP), which included dogs without major protocol violations.
The primary variable used to assess efficacy was based on the
CBPI. For each dog, treatment success was defined for post-
treatment time points as: (1) a decrease in PSS of at least one
from baseline, and (2) a decrease in PIS of at least 1 from baseline
(18). Any dog that did not meet this criterion for success was
considered a failure. Failure was carried forward, where each dog
assessed as a treatment failure at a post-treatment time point was
considered as a treatment failure at subsequent time points. Dogs
that were withdrawn from the study as the result of perceived
lack of efficacy by owner or veterinarian were also considered as
treatment failure. Success rates were compared between groups
at each time point with a Chi-squared test.
Secondary outcome variables compared between groups in
the PPP at each time point were: sum indexed orthopedic
examination scores, sum indexed HVAS scores, and PVF
of the affected limb. Comparisons were performed with a
repeated measures analysis of covariance, with baseline values




One-hundred and seventeen dogs were assessed for eligibility,
of which 55 dogs met the inclusion criteria and were enrolled
into the study (Figure 1). The main reasons for initial exclusion
were lack of lameness (n = 15), pelvic limb lameness (n =
12), and other cause of forelimb lameness (n = 8). In the ITT
population, 30 dogs were allocated to the UMSC group, and
25 dogs were allocated to the placebo group. There were two
dogs in the UMSC group that did not qualify for the PPP:
one dog developed gastrointestinal perforation due to multiple
concomitant NSAID administration that was not prescribed by
a veterinarian at 30 days from treatment, and the wrong joint
was injected in one dog. There were also two dogs in the placebo
group that did not qualify for the PPP: one dog had unexplained
and frequent shifting forelimb lameness noted in the first month
after treatment, and one dog was administered Adequan in the
first month after treatment. Therefore, a total of 51 dogs were
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FIGURE 1 | Case flow indicating how the safety (intent to treat) and per protocol populations were identified for the UMSC and placebo treatment groups.
included in the PPP, with 28 dogs in the UMSC group and 23 dogs
in the placebo group. There was no significant difference in age,
body weight, proportion of dogs with NSAID use, and symmetry
index between groups in the PPP (Table 1).
Within the PPP, bilateral elbow OA was evident on CT
in 26/28 dogs (93%) and 17/23 dogs (74%) in the UMSC
and placebo groups, respectively; there was no significant
difference in the frequency of bilateral elbow OA between groups
(P = 0.642). Based on CT findings, medial coronoid disease
was suspected as the underlying disease process in all elbows
with OA.
Safety
No dogs in either group developed worsening of lameness
following treatment that warranted removal from the study.
Acute worsening of lameness was seen in one dog in the placebo
group at 11 days following saline injection; however, the degree
of lameness was not considered severe enough for either the
owner or veterinarian to withdraw the dog from the study. Joint
fluid cytology in that dog was consistent with OA, and the
dog’s exacerbation of lameness resolved after a 1 week period
of rest. No other local adverse effects were noted in any dog,
including any worsening of pain and swelling, or discharge from
the treated elbow.
Serious adverse events occurred in five dogs in the UMSC
group, and two dogs in the placebo group (Table 2). All of the
serious adverse events were classified as unlikely to be related to
treatment. One of the dogs in the UMSC group was excluded
from the PPP because the serious adverse event occurred prior
to the day 30 evaluation. The serious adverse events in the other
four dogs of the UMSC group necessitated withdrawal of the dogs
from the study between the day 30 and day 90 evaluation. A single
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dog in the placebo group was withdrawn from the study at the
day 90 evaluation due to the development of clinically significant
bicipital tenosynovitis.










Male 14 (60.9%) 14 (50.0%) 28 (54.9%) 0.44
Female 9 (39.1%) 14 (50.0%) 23 (45.1%)
Age (y)
Mean (SD) 6.2 (3.3) 7.2 (2.6) 6.7 (3.0) 0.26
Median 7.0 8.0 7.0
Min, Max 1.0, 11.0 2.0, 11.0 1.0, 11.0
Weight (kg)
Mean (SD) 29.7 (9.0) 32.6 (8.3) 31.3 (8.7) 0.23
Median 30.7 31.9 31.8
Min, Max 11.5, 49.5 19.2, 59.1 11.5, 59.1
Body condition score
5 9 (39.1%) 12 (42.9%) 21 (41.2%) 0.16
6 7 (30.4%) 9 (32.1%) 16 (31.4%)
7 4 (17.4%) 7 (25.0%) 11 (21.6%)
8 3 (13.0%) 0 (0.0%) 3 (5.9%)
Concurrent Medications
Yes 15 (65.2%) 16 (57.1%) 31 (60.8%) 0.56
No 8 (34.8%) 12 (42.9%) 20 (39.2%)
Symmetry index
Mean (SD) −5.8 (3.5) −6.5 (4.6) −6.2 (4.2) 0.57
Median −5.7 −5.5 −5.6
Min, Max −12.9, −0.2 −20.3, −0.3 −20.3, −0.2
Owner-Assessed Outcomes
Treatment success based on CBPI at 1 month was observed
in 15/28 UMSC dogs (54%) and 6/23 placebo dogs (28%);
Treatment success based on CBPI at 3 months was observed
in 12/24 UMSC dogs (50%) and 5/23 placebo dogs (27%)
(Table 3). Treatment success based on CBPI at 6 months was
observed in 11/24 UMSC dogs (46%) and 3/23 placebo dogs
(14%). The treatment success rate in the UMSC group was
significantly higher than the placebo group at 1 and 6 months
after treatment, but no difference (P = 0.056) was observed
at 3 months.
The mean HVAS Mood and sum indexed HVAS scores
were both significantly improved following treatment in the
UMSC group, whereas no significant differences over time were
observed for the placebo group (Table 4). The mean HVAS
Movement scores were also significantly improved following
treatment in the UMSC group, whereas a significant difference
from baseline was only observed at 3 months following treatment
for the placebo group. There was a significant difference in HVAS
Mood scores between treatment groups at 3 (P = 0.05) and 6
(P = 0.01) months, but there was no difference at 1 month (P
= 0.06). There was a significant difference in HVAS sum scores
between treatment groups 6 months (P = 0.03), but there was no
difference at 1 month (P = 0.07).
TABLE 3 | Success rates based on CBPI results.
1 month 3 months 6 months
Sample sizes (stem cell group, placebo group) 28, 23 24, 22 24, 22
UMSC group success rate n (%) 15 (54%) 12 (50%) 11 (46%)
Placebo group success rate n (%) 6 (26%) 5 (23%) 3 (14%)
Difference in rates 28% 27% 32%
Chi-Square p-value 0.047 0.056 0.018





Type of event Concomitant
medications
Differential diagnosis Estimated relationship to
treatment by Veterinarian
Outcome




Unlikely related to treatment Humane euthanasia











Unlikely related to treatment Humane Euthanasia
UMSC 310 Peripheral
lymphadenomegaly
None Lymphoma (confirmed) Unlikely related to treatment Treatment with
prednisone











Unlikely related to treatment Treatment with rest,
NSAIDs




Unlikely related to treatment Nasal planum resection
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TABLE 4A | Mean HVAS movement scores.
Baseline 1 Month 3 Months 6 Months
UMSC mean 26.80 36.50a 40.64a 40.20a
Placebo mean 27.84 31.04 34.77a 32.65
Difference in means −1.04 5.46 5.87 7.55
p-value (UMSC vs. control) 0.72 0.06 0.05 0.01
aSignificantly different from baseline within group.
TABLE 4B | Mean HVAS mood scores.
Baseline 1 month 3 months 6 months
UMSC mean 24.91 29.57a 30.28a 29.56a
Placebo mean 25.42 27.08 28.99 27.11
Difference in means −0.51 2.49 1.30 2.44
p-value (UMSC vs. control) 0.77 0.16 0.48 0.19
aSignificantly different from baseline within group.
TABLE 4C | Mean HVAS total scores.
Baseline 1 month 3 months 6 months
UMSC mean 51.61 65.98a 70.80a 69.65a
Placebo mean 53.39 58.25 63.85 59.84
Difference in means −1.78 7.73 6.95 9.81
p-value (UMSC vs. control) 0.68 0.07 0.12 0.03
a Significantly different from baseline within group.
TABLE 4D | Mean summed orthopedic examination score.
Baseline 1 month 3 months 6 months
UMSC mean 13.25 11.57 11.60 11.60
Placebo mean 13.32 12.36 11.96 12.60
Difference in means −0.07 −0.79 −0.36 −1.00
p-value (UMSC vs. control) 0.95 0.47 0.76 0.39
TABLE 4E | Mean Force Plate PVF on lame limb.
Baseline 1 month 3 months 6 months
UMSC mean 85.56 91.56 88.22 91.33
Placebo mean 86.05 84.91 92.02 92.43
Difference in means −0.49 6.66 −4.20 −1.10
p-value 0.87 0.02 0.22 0.69
Orthopedic Examination and Force-Plate
Analysis
The covariates of baseline values had no significant effects on the
models for both orthopedic examination scores and force plate
analysis values. No differences in PVF of the affected limb over
time was observed in either treatment group (Table 4). Higher
PVF was evident in the UMSC group when compared to placebo
at 1 month following treatment (P= 0.02); however, there was no
significant difference in PVF between groups at 3 or 6months. No
differences in the sum-indexed orthopedic scores were detected
over time in either treatment group, or between treatment groups
at equivalent time points.
DISCUSSION
This prospective clinical study of intra-articular UMSC therapy
for canine elbow OA was both blinded and placebo controlled.
According to the primary outcome variable based on owner
assessment, a single intra-articular injection of allogenic UMSC
reduced clinical signs of OA, when compared to a saline
placebo. The positive effect appeared to persist throughout the
6 month duration of the study. None of the adverse events
occurring in the UMSC group were found to be related to the
treatment, which is of particular importance since this is the
first study to assess the use of allogenic UMCS in a veterinary
clinical setting.
Although the study detected statistical difference in success
rates between treatment groups, our results should be interpreted
in light of many factors when making clinical recommendations.
The success rates based on CBPI in dogs treated with
intra-articular UMSC ranged from 46 to 54%, which were
approximately twice as high as the success rates in the placebo
group. Whereas the response to treatment in this study may
appear disappointing, we suspect low success rates found with
both groups may be a reflection of the rigorous definition of
success, rather than an inconsistent response to the treatment
(22). Indeed, the response rates in our study were comparable
to those reported in a study evaluating carprofen, which is
considered to be a well-established and reliable therapeutic for
dogs with OA (22).
Since quantifying clinical improvements directly related to
therapeutics can be difficult in dogs with OA, numerous outcome
measures have been developed. Our study used multiple tools
for evaluating efficacy, but the proportion of dogs having success
within a group based on CBPI was designated as the primary
outcome. By reporting the percentage of dogs reaching a pre-
determined level of improvement that is deemed clinically
relevant, the results may give a greater sense of how likely an
individual animal will respond favorably, when compared to
reporting average scores for a group (22). This method is also less
prone to being misinterpreted because of extreme outliers, which
can have a large influence on mean or median values for pooled
data (7, 18, 22). However, defining a clinically relevant target
value, which defines success of the treatment, is highly subjective.
In our study success was defined as a decrease in both PIS and
PSS scores by at least one in dogs with baseline PIS and PSS of
>2; this criterion was previously proven to be a robust method
for comparing response to treatments for OA in dogs (22).
It has also been suggested that owner-assessed outcomes such
as CBPI are superior to veterinarian-based outcomes, because
owners are able to observe dogs for much longer durations
in familiar environments (18, 22). For these reasons, the FDA
requires studies to utilize owner assessed outcome measures with
classification of each animal as a success or failure.
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Response to UMCS treatment appeared to sustain over the
6 months duration of follow-up. Based on our study design,
the proportion of successful cases in the UMSC group would
have approached the levels identified in the placebo group if
the duration of response to UMCS was <6 months; however,
success rates were approximately twice as high in the UMSC
group throughout the follow-up period. It should be noted that
a difference was not found at the 3 month time point. The lack of
significance may have been caused by a Type-II statistical error,
since a) the magnitude of difference between groups was similar
for all post-treatment time points, and b) the number of subjects
completing the study was below the original target set by the pre-
study power analysis, suggesting the study was under-powered.
A prolonged duration of effect is especially desirable because
moderate to profound sedation is typically required for precise
intra-articular injection, which may carry higher risks in an older
population of dogs. Two previous clinical studies of autologous
adipose-derived MSC in dogs with OA also found significant
improvements for up to 6 months (3, 9). Collectively, these
results suggest future studies should be designed to continue
observations for>6months in order to better define the expected
duration of effects associated with stem cell therapy for OA.
Secondary outcome measures, including HVAS scores,
force-platform gait analysis, and veterinarian-based examination
scores, did not consistently identify differences between
treatment groups. The HVAS scores improved in the UMSC
group, but not the placebo group; however, significant differences
between groups at equivalent time points were sporadic.
Additionally, UMSC therapy did not appear to have an effect
on veterinarian-based examination scores and force-platform
gait analysis. Weak correlations between PVF and owner based
assessments such as CBPI have been previously demonstrated
(23), and the discrepancy of owner-based vs. veterinarian-
based findings in this study could be explained by several
possibilities. As discussed above, owner assessments are based
on observing familiar subjects over a much longer period of
time in their comfortable environment, and thus owners may
have greater abilities to discern subtle responses. The owner
questionnaires account for overall mobility and comfort, whereas
the force-platform gait analysis and veterinarian examination
more specifically evaluates the treated limb. The veterinarian
assessment performed in this study encompassed parameters
such as joint thickening and range of motion, and stem cell
therapy is unlikely to reverse these types of chronic pathologic
changes. Indeed, percutaneous delivery of stem cells within
osteoarthritic joints are not expected to have any regenerative
effect; rather, the proposed mechanism of action relates to
modulation of inflammatory mediators (14). It is also possible
that owner-bias played a role, where owners could be more
hopeful for a positive response. Based on our force-platform and
veterinarian-examination results, stem cell therapy alone may
not have the ability to substantially improve lameness in dogs
with chronic elbow OA, where structural changes of the joint
may be a major contributor to limb dysfunction.
Stem cell therapy was very well-tolerated, and none of the
dogs in the study developed adverse events that were likely to be
related to UMSC treatment. Our findings are similar to studies
in animals and humans reporting no adverse effects following
intra-articular MSC treatment (5, 7, 24). The lack of side effects
of MSC is attractive, because other intra-articular treatments for
OA such as corticosteroids have reported risks associated with
cytotoxicity, anaphylactic reactions or septic arthritis (25–27).
Because of its safety, intra-articular UMSC may be particularly
attractive for long term management of OA.
Despite some evidence showing MSC can be recognized by
the host immune system (28), we did not observe any rejection
response in our study. While promising, we only administered
a single injection and potential adverse effects associated with
repeated injections is unknown. The UMSC preparation in this
study underwent rigorous quality control, including screening
for infectious agents and use of strict sterile techniques. While
there were two dogs in the UMSC group that developed neoplasia
(hemangiosarcoma, lymphoma), the malignancies were not
related to the treated joint. No animal studies have documented
evidence of neoplasms at stem cell implantation sites, and the
safety of intra-articular stem cell therapy in humans was recently
confirmed in a large systematic literature review (29). It should
be noted that most of the cited studies in that review were
investigating autologous therapies, and the safety of allogenic
UMSC needs further investigation.
Clinical efficacy of intra-articular MSC therapy for canine OA
has been shown with both autologous and allogenic adipose-
derived MSC in prospective, blinded clinical investigations (3,
4, 7, 9, 10). While it is not possible to accurately compare
efficacy between studies, the umbilical source used in this study
does offer several advantages over the described adipose-derived
MSC. Harvest of autogenous adipose-derivedMSC are associated
with additional morbidity and cost, as surgical removal of fat is
required. Cesarean section is a prerequisite for collecting UMSC;
however, the decision to elect surgery is not in any way related to
collection of the cells. It should be noted that allogenic adiposed-
derived MSC may also be obtained ethically from “waste” tissue
such as falciform fat during a laparotomy that was not performed
specifically for the purposes of collecting MSC. The quantity
and quality of MSC from adult bone marrow or adipose tissue
can decline and/or become more variable with donor age (30,
31), whereas previous studies suggest UMCS may have greater
proliferative and differentiating abilities than MCS derived from
other sources (32).
There are several limitations to this study. We adopted less
stringent definitions of success based on CBPI, as a reduction
of PIS ≥2 (not 1) is more commonly used (22, 33); the optimal
application of CBPI under different testing conditions remains to
be determined. Although clinical improvement was documented,
the results do not give any further insight into the mechanism of
action of stem cell therapy for OA. The response to treatment
was variable, and may have been influenced by several factors
such as the severity of OA; for instance, dogs with complete
loss of cartilage and severe OA may not have responded as
well to this treatment when compared to those dogs with mild
OA. Unfortunately, low case numbers precluded the ability to
investigate factors contributing to a poor response. The vast
majority of dogs had bilateral disease, yet the contralateral limb
remained un-treated. Future studies should consider treatment of
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all joints assessed to be contributing to pain. Both the safety and
efficacy of UMSC were not assessed for longer than 6 months,
meaning longer term outcomes and adverse effects are unknown.
The results of this study demonstrated improvement of
clinical signs related to elbow OA in dogs treated with intra-
articular UMCS based on owner observations. Both objective
and subjective veterinarian-based assessments were unable to
distinguish between dogs treated with UMSC and a saline
placebo, suggesting the effect of stem cell therapy may be limited.
Encouragingly, intra-articular UMSC appear to have a prolonged
duration of effect with minimal risk of complications. This
treatment therefore may be a suitable alternative to conventional
therapeutics for OA in dogs, but one should be aware of the
relatively limited effect.
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